R(+)XK469 in Treating Patients With Advanced Neuroblastoma

NCT00028522 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

85

Enrollment

NIH

Sponsor class

Conditions

Disseminated Neuroblastoma
Localized Unresectable Neuroblastoma
Recurrent Neuroblastoma
Regional Neuroblastoma

Interventions

DRUG: R(+)XK469

Sponsor

National Cancer Institute (NCI)